期刊
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
卷 1762, 期 6, 页码 587-591出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbadis.2006.04.001
关键词
autoantibody-based EIA; cancer detection; biomarker; autoantibody ECPKA; cAMP-dependent protein kinase
资金
- Intramural NIH HHS Funding Source: Medline
- NATIONAL CANCER INSTITUTE [Z01BC005216, Z01BC008281] Funding Source: NIH RePORTER
By definition, tumor biomarkers are selective molecules that can distinguish between patients with cancer and controls. Serum tumor markers have been the most widely used approach for cancer detection. However, the limitations of these markers, which are based on the measurement of tumor antigens, preclude their general use in cancer screening and diagnosis. Here we give an over-view of recent cancer biomarker developments based on the detection of autoantibodies produced against tumor antigens in patients' sera. This new detection method can measure the autoantibodies for a spectrum of tumor antigens in a single assay, with sensitivity and specificity exceeding those obtained using the conventional antigen determination method. Autoantibodies against serum cancer biomarkers offer a novel technology for cancer detection. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据